Latest Articles

Few recent drug launches have scaled as quickly as Rezdiffra, and the company behind it, Madrigal Pharmaceuticals, has become a case study in what a first-in-disease approval can do for a single-product biotech. Madrigal built its business around resmetirom, sold as Rezdiffra, the first therapy cleared by the FDA for…